Tuesday, June 20, 2006

Biotech News - Industry Insight -Indian Biotechnology

Industry Insight -Indian Biotechnology
CYGNUS Business Consulting & Research, Jan 2005, Pages: 120

Analytical inputs on "how the industry is moving towards high growth".
It lays emphasis on region-wise biotechnological development and
emerging technologies. The report comprises Global Biotech Overview
which includes the status of global biotech industry with the analysis
of major players, products and major markets. Indian Biotech Overview
covers the milestones of the industry and how it has taken the present
shape including the analytical inputs on industry structure - size,
strength of Indian companies, various segments, exports and government
support.

http://www.researchandmarkets.com/reports/c38414/

------------------------ Yahoo! Groups Sponsor --------------------~-->
Something is new at Yahoo! Groups. Check out the enhanced email design.
http://us.click.yahoo.com/qTZcGA/gOaOAA/79vVAA/H4xqlB/TM
--------------------------------------------------------------------~->

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News - Mission3 Announces Strategic Partnership With TGen Affiliate TD2

Mission3 Announces Strategic Partnership With TGen Affiliate TD2

Mission3, Inc. today announced that they have joined a strategic
partnership with TD2, the drug development affiliate of the
Translational Genomics Research Institute (TGen) to aid in
developing oncology therapeutics.

For Immediate Release

PHOENIX/EWORLDWIRE/June 19, 2006 --- Mission3, Inc., a leading
provider of document and project management software serving the
life sciences industry today announced that it has joined a
strategic partnership with TGen Drug Development Services (TD2), the
non-profit drug development affiliate of the Translational Genomics
Research Institute (TGen) to aid in developing oncology
therapeutics.

"MissionFire allows life science organizations to manage their
mission-critical content and processes in a cost effective manner.
This enterprise software application enables companies to take
control of their project management and documentation in one
centralized Web-based environment, allowing for an efficient and
effective use of resources," said Dirk Karsten Beth, president of
Mission3, Inc. "With rich features in project management and
document management, it was designed specifically for the Life
Sciences industry to facilitate electronic submissions with the FDA."

"This software is a valuable tool that will help us get promising
new cancer treatments to patients as quickly and safely as possible,
while continuing to meet stringent Federal regulations," said TD2
general manager Steve Marsh.

------------------------ Yahoo! Groups Sponsor --------------------~-->
Yahoo! Groups gets a make over. See the new email design.
http://us.click.yahoo.com/vTZcGA/lOaOAA/79vVAA/H4xqlB/TM
--------------------------------------------------------------------~->

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News - Manchester facility boosts biotechnology

The Engineer OnlineTuesday - 20 June 2006Business News
Manchester facility boosts biotechnology
Email articleComment on this articlePublished: 16 June 2006 04:00 PM
Industry Channel: Medical & Pharmaceutical
Source: The Engineer Online

A new £25 million facility dedicated to finding new treatments for
diseases such as HIV and cancer was launched at The University of
Manchester today.

The Core Technology Facility (CTF) labs are already looking at ways
to grow replacement tissue, such as veins and arteries, and even
whole organs that could one day be transplanted into patients
suffering from conditions such as heart disease and diabetes.

The CTF will provide specialist accommodation for biotech companies
as well as academic staff from the university's Faculties of Life
Sciences and Medical and Human Sciences.

The facility will encourage commercial exploitation of these
university research activities by providing integrated space in
which young businesses can work alongside University research
groups. The CTF is being launched by The University of Manchester
Incubator Company Limited (UMIC), which manages a portfolio of
business incubators on behalf of the university

http://www.e4engineering.com/Articles/294912/Manchester%20facility%
20boosts%20biotechnology.htm

------------------------ Yahoo! Groups Sponsor --------------------~-->
Great things are happening at Yahoo! Groups. See the new email design.
http://us.click.yahoo.com/rTZcGA/hOaOAA/79vVAA/H4xqlB/TM
--------------------------------------------------------------------~->

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Thursday, June 15, 2006

Chandler planning biotech facility

Chandler planning biotech facility
By Chris Markham, Tribune

June 12, 2006
Chandler officials don’t want to place all of their economic development eggs in one basket — instead, they want to hatch some in a $15 million bioscience technology “incubator.”


The City Council recently approved an $81,000 contract to begin planning a community technology incubator and accelerator that economic development officials say would help diversify Chandler’s already strong foothold in the high-tech arena. The facility would help fledgling bioscience companies, especially those in the nanotechnology field, get off the ground.

“Chandler is already a signature technology community,” said Christine MacKay, an economic development specialist for the city. She specifically noted Intel and Motorola, which both have large facilities there.


Biotech News - New Report Analyzes Pharmaceutical Market Segmentation Spending, Strategy and Im

New Report Analyzes Pharmaceutical Market Segmentation Spending,
Strategy and Implementation
Thursday June 15, 9:55 am ET

RESEARCH TRIANGLE PARK, N.C., June 15 /PRNewswire/ -- Pharmaceutical
business intelligence leader Cutting Edge Information announces the
launch of a new report, "Pharmaceutical Market Segmentation:
Spending, Strategy and Implementation"
ADVERTISEMENT


(http://www.cuttingedgeinfo.com/pharmamarketsegmentation/index.htm).

The report assesses real pharmaceutical companies' market
segmentation spending, structures, strategies, staffing and
implementation practices. Compiled from interviews and surveys with
marketing, market research and sales executives in the
pharmaceutical and biotech industries, the report allows drug
companies to compare and improve their own market segmentation
methodologies.

With the industry reversing course on sales force expansion,
companies are in need of finding more effective sales practices.
Rather than dominating the market through sheer number of sales
reps, companies are developing more targeted marketing campaigns -
aimed at selling to the right candidates, in the right way.

Pharmaceutical companies use market segmentation techniques to slice
their sales targets - be they physicians, consumers, or insurance
payors - into groups based on factors as simple as demographics,
geography or prescription volume. More sophisticated companies add
measures including behaviors, attitudes, and psychographics to their
segmentation plans. Compiling these factors and grouping targets
based on their characteristics allows companies to develop campaigns
that hit targets with the most effective messages through the most
effective mediums.

"This report can help pharmaceutical and biotech companies develop
stronger and more effective market segmentation strategies. Our
research shows the resources companies dedicate to market
segmentation, how real companies grade the various segmentation
techniques in terms of their effectiveness, and how companies
overcome many of the challenges associated with segmentation
implementation," says David Richardson, senior research analyst at
Cutting Edge Information. "With sales force expansion slowing
tremendously and even reversing course, companies are trying to find
more effective ways of reaching their key targets - and influencing
their actions. Market segmentation is helping them do this."

According to Richardson, companies need to keep pace with the
industry leaders in terms of effectively reaching their target
markets. Otherwise, their brands could get lost in crowded markets.

To view a summary of this report, visit
http://www.cuttingedgeinfo.com/pharmamarketsegmentation/index.htm.
For more information about Cutting Edge Information's new report,
contact David Richardson at David_Richardson@cuttingedgeinfo.com or
919-433-0216.

---------------------------------------------------------------------
-----------
Source: Cutting Edge Information

------------------------ Yahoo! Groups Sponsor --------------------~-->
See what's inside the new Yahoo! Groups email.
http://us.click.yahoo.com/2pRQfA/bOaOAA/yQLSAA/H4xqlB/TM
--------------------------------------------------------------------~->

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News - Favrille Announces FDA Allowance of Investigational New Drug Application for FAV

Favrille Announces FDA Allowance of Investigational New Drug
Application for FAV-201, a Patient-Specific Immunotherapy for T-Cell
Lymphoma
Thursday June 15, 6:30 am ET

SAN DIEGO, June 15 /PRNewswire-FirstCall/ -- Favrille, Inc. (Nasdaq:
FVRL - News), a biopharmaceutical company developing patient-
specific immunotherapies for the treatment of cancer, announced
today that its electronic Investigational New Drug (IND) application
for FAV-201, a patient-specific immunotherapy for the treatment of T-
cell lymphoma, has been cleared by the U.S. Food & Drug
Administration (FDA). Initially, FAV-201 will be evaluated in
cutaneous T-cell lymphoma (CTCL).
ADVERTISEMENT


(Logo: http://www.newscom.com/cgi-bin/prnh/20031013/LAM095LOGO )

"This new product candidate represents an extension of our platform
and draws on our success to date in the development of our lead
product candidate FavId® for the treatment of B-cell non-Hodgkin's
lymphoma (NHL)," said John P. Longenecker, Ph.D., President and
Chief Executive Officer of Favrille. "This regulatory clearance by
the FDA is an important milestone in the development of FAV-201 and
we look forward to introducing it in the clinic."

Favrille intends to initiate a Phase 1/2 clinical trial evaluating
the safety and biologic activity of FAV-201 in patients with CTCL.
The trial will build upon preclinical data that suggest activity of
an immunotherapy based on a T-cell receptor. The multi-center trial
is expected to enroll approximately 30 patients.

FAV-201 is a recombinant, patient-specific, T-cell receptor-based
immunotherapy designed to induce an active immune response against
the unique protein found on the surface of T-cells that constitute a
patient's lymphoma. Favrille uses a similar approach with its lead
product candidate FavId for the treatment of B-cell NHL. In January
the Company completed enrollment in a pivotal Phase 3 clinical trial
of FavId following induction therapy with Rituxan®, the current
standard of care. Favrille has received Fast Track designation from
the FDA for FavId.

About Favrille, Inc.

Favrille, Inc. is a biopharmaceutical company focused on the
development and commercialization of targeted immunotherapies for
the treatment of cancer and other diseases of the immune system. The
Company's lead product candidate, FavId, is based upon unique
genetic information extracted from a patient's tumor. FavId is
currently under investigation in a pivotal Phase 3 clinical trial
for patients with follicular B-cell NHL and Phase 2 clinical trials
in other B-cell NHL indications. The Company is developing
additional applications based on its immunotherapy expertise and
proprietary cost-effective manufacturing technology, including a
second product candidate, FAV-201, for the treatment of cutaneous T-
cell lymphoma.

Statements in this press release that are not strictly historical in
nature constitute "forward-looking statements." Such statements
include, but are not limited to, references to Favrille's product
candidates, proprietary technologies and research programs. Such
forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause Favrille's actual
results to be materially different from historical results or from
any results expressed or implied by such forward-looking statements.
These factors include, but are not limited to, risks and
uncertainties related to progress and timing of clinical trials for
FavId or FAV-201, including difficulties or delays in development,
testing, manufacturing and marketing FavId, FAV-201 or Favrille's
other product candidates; Favrille's ability to obtain marketing
approval for FavId, FAV-201 or Favrille's other product candidates
and the timing of any such approvals; Favrille's ability to
manufacture sufficient quantities of FavId or FAV-201 for use in
clinical trials and, if FavId or FAV-201 receive marketing approval,
for commercialization; risks associated with achieving projected
operating metrics and financial performance or the anticipated
number of patients using FavId or FAV-201; potential delays in
patient enrollment; Favrille's ability to obtain additional
financing to support its operations; and additional risks discussed
in Favrille's filings with the Securities and Exchange Commission.
In addition, conclusions regarding the safety and efficacy of
Favrille's product candidates cannot be made until the results of
future clinical trials of longer duration in more patients are
known. All forward-looking statements are qualified in their
entirety by this cautionary statement. Favrille is providing this
information as of the date of this release and, except as required
by law, does not undertake any obligation to update any forward-
looking statements contained in this release as a result of new
information, future events or otherwise.

---------------------------------------------------------------------
-----------
Source: Favrille, Inc.

------------------------ Yahoo! Groups Sponsor --------------------~-->
Check out the new improvements in Yahoo! Groups email.
http://us.click.yahoo.com/6pRQfA/fOaOAA/yQLSAA/H4xqlB/TM
--------------------------------------------------------------------~->

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News - Upstream Biosciences Inc. Appoints University of British Columbia Dean of Pharma

Upstream Biosciences Inc. Appoints University of British Columbia
Dean of Pharmaceutical Sciences Robert Sindelar to Scientific
Advisory Board
VANCOUVER, BC -- (MARKET WIRE) -- 06/14/2006 -- Upstream Biosciences
Inc. (OTCBB: UPBS) ("Upstream" or "the Company"), an emerging leader
in the field of genetic diagnostics for cancer and the prediction of
drug response, has announced today the appointment of Dr. Robert D.
Sindelar to its scientific advisory board. Dr. Sindelar is Professor
and Dean of the Faculty of Pharmaceutical Sciences at The University
of British Columbia.

Dr. Sindelar's expertise lies in medicinal chemistry, computer-aided
drug discovery and design, pharmaceutical biotechnology, and
creating opportunities to integrate innovation into the health care
system. He maintained an active research program that focused on the
human immune system and drug design for related diseases. This work
resulted in more than $14 million (US$) in extramural funding as
Principle (PI) and Co-PI Investigator, about 60 refereed journal
articles, six U.S. patents, several foreign patents and over 100
scientific and professional presentations. He serves as a member of
the editorial boards of various scientific journals, including The
APhA Biotechnology Initiative, Current Medicinal Chemistry, Current
Patents in Infectious Diseases, Medicinal Chemistry, and the journal
IDrugs: The Investigational New Drug Journal. Besides having co-
edited a popular textbook on pharmaceutical biotechnology, which has
been translated into several languages, Dr. Sindelar is the
recipient of several School and University-wide teaching honors. In
addition to his leadership role in the Faculty, Dr. Sindelar
continues to teach in the professional undergraduate curriculum in
several courses. He has been active in promoting the profession of
pharmacy, the BC biotechnology community and life sciences research
with numerous government and health care stakeholders at the
national and local levels. He currently sits on the Council of The
College of Pharmacists of British Columbia, serves on the Board of
Directors of BC Biotech and serves on other scientific advisory
boards.

"Dr. Sindelar's extensive experience in the pharmaceutical sciences
coupled with his knowledge of the healthcare system could help
accelerate our research," says Upstream CEO Joel Bellenson. "We are
pleased to add another prominent member of the healthcare community
to our team."

"Genetics will play an ever-increasing role in explaining, and
eventually predicting, the effectiveness of drug therapy," says Dr.
Sindelar. "A patient's genetic profile can have a significant impact
on drug response, both the desired effect, but also adverse drug
reactions."

Upstream is developing diagnostic tests that may aid in the early
detection of cancer by identifying individuals with disease
susceptibility. Upstream is also developing diagnostic tests that
may determine whether a drug will be useful or harmful to an
individual patient based on their genetic profile. According to the
Journal of the American Medical Association, each year 100,000
people die in the United States due to adverse reactions to
prescription drugs.

About Upstream Biosciences Inc.

Upstream Biosciences Inc. is an emerging leader in the field of
genetic diagnostics for cancer and the prediction of drug response
founded in 2004. Upstream discovers, develops, and licenses genetic-
based diagnostics for cancer susceptibility and drug response.
Upstream's proprietary data mining pipeline enables it to locate and
analyze genetic variations in the regions of DNA 'upstream' of the
gene, the 'gene switches,' which control the quantities and timing
of expression of the genes and proteins important to disease and
drug response.

Notice Regarding Forward-Looking Statements

This news release contains "forward-looking statements," as that
term is defined in Section 27A of the United States Securities Act
of 1933, as amended, and Section 21E of the United States Securities
Exchange Act of 1934, as amended. Statements in this press release,
which are not purely historical, are forward-looking statements and
include any statements regarding beliefs, plans, expectations or
intentions regarding the future. Such forward-looking statements
include, among others, the expectation and/or claim, as applicable,
that: (i) the Company may become an emerging leader in the field of
diagnostics for cancer and the prediction of drug response; (ii) Dr.
Sindelar can help the Company discover effective diagnostic tools;
(iii) genetic research could have a major impact in the field of
diagnostics; (iv) Dr. Sindelar may assist the Company in discovering
new diagnostic markers; (v) the Company is developing diagnostic
tests that may aid in the early detection of cancer by identifying
individuals with disease susceptibility; (vi) the Company is
developing diagnostic tests that may determine whether a drug will
be useful or harmful to an individual patient based on their genetic
profile; (vii) the Company may discover, develop and license its
genetic based diagnostics for cancer susceptibility and drug
response; and (viii) the Company's data mining pipeline may enable
the Company to locate and analyze genetic variations in the regions
of DNA which control the quantities and timing of expression of the
genes and proteins important to disease and drug response.

Actual results could differ from those projected in any forward-
looking statements due to numerous factors. Such factors include,
among others: (i) the risk that the Company does not execute its
business plan; (ii) the inability of the Company to keep pace with
technological advancements in the field of genetic diagnostics;
(iii) the Company's inability to adequately protect its intellectual
property or the Company's inadvertent infringement of third party
intellectual property; (iv) the Company not being able to retain key
employees; (v) competitors providing better or cheaper products and
technologies; (vi) markets for the Company's products not developing
as expected; (vii) the Company's inability to finance its operations
or growth; (viii) inability to obtain all necessary government and
regulatory approvals; and (ix) the inability to effectively market
and commercialize the Company's technologies, including the
establishment of viable relationships with third parties. These
forward-looking statements are made as of the date of this news
release and the Company assumes no obligation to update the forward-
looking statements, or to update the reasons why actual results
could differ from those projected in the forward-looking statements.
Although the Company believes that the beliefs, plans, expectations
and intentions contained in this press release are reasonable, there
can be no assurance those beliefs, plans, expectations, or
intentions will prove to be accurate. Investors should consider all
of the information set forth herein and should also refer to the
risk factors disclosed in the Company's periodic reports filed from
time-to-time with the Securities and Exchange Commission and
available at www.sec.gov.

Distributed by Filing Services Canada and retransmitted by Market
Wire


---------------------------------------------------------------------
-----------

For more information, please contact:
Samantha Haynes
1-800-539-0289
Email Contact

SOURCE: Upstream Biosciences Inc.

------------------------ Yahoo! Groups Sponsor --------------------~-->
Great things are happening at Yahoo! Groups. See the new email design.
http://us.click.yahoo.com/TISQkA/hOaOAA/yQLSAA/H4xqlB/TM
--------------------------------------------------------------------~->

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News - PAREXEL Experts to Participate in 42nd Annual Drug Information Association Meeti

PAREXEL Experts to Participate in 42nd Annual Drug Information
Association Meeting
Wednesday June 14, 10:32 am ET

BOSTON, June 14 /PRNewswire-FirstCall/ -- Several experts from
PAREXEL International Corporation (Nasdaq: PRXL - News), a leading
global bio/pharmaceutical services organization, will chair sessions
and give presentations during the 42nd Annual Drug Information
Association (DIA) Meeting, to be held June 18 - 22, 2006 at the
Pennsylvania Convention Center in Philadelphia. Significant industry
issues will be addressed, including the changing paradigm of
clinical development programs, biosimilars, biomarkers in drug
development, and success factors for global applications of
biotechnology-derived products.
PAREXEL will also have a major presence in the exhibit hall at
booths 925 - 1024 to showcase services from its business units:
PAREXEL Consulting, PAREXEL Clinical Research, PAREXEL Medical
Communications and its technology subsidiary Perceptive Informatics,
Inc.

PAREXEL Presentations

Monday, June 19
Chair: Alberto Grignolo, Corporate Vice President and
General
Manager, PAREXEL Consulting
Session: "Changing the Paradigm: Innovation Oncology Drug
Clinical
Development Programs in the Age of Critical Path and
Personalized Medicine"
Time: 10:30 a.m. - 12:00 p.m.

Tuesday, June 20
Chair: Cecil Nick, Director, PAREXEL Consulting, UK
Session: "Biosimilars in Europe: A Dawning Reality"
Time: 10:30 a.m. - 12:00 p.m.

Chair: Alberto Grignolo, Corporate Vice President and
General
Manager, PAREXEL Consulting
Session: "Biomarkers in Drug Development: A Blessing or a
Curse?"
Time: 1:30 p.m. - 3:00 p.m.

Wednesday, June 21
Presenter: David Davenport, Senior Director, Business
Development,
Perceptive Informatics
Session: "Tracking Patient Enrollment from Inquiry to
Randomization and
Beyond"
Time: 3:30 p.m. - 5:00 p.m.

Chair: Gabriele Schaeffner, Principal Consultant, PAREXEL
Consulting
Session: "An Analysis of the Success Factors of Global
Applications of
Biotechnology-derived Products"
Time: 3:30 p.m. - 5:00 p.m.

Thursday, June 22
Chair: David Skarinsky, Principal Consultant, PAREXEL
Consulting
Session: "Microdosing Studies: State of Technology and US
Regulatory
Requirements"
Time: 8:30 a.m. - 10:00 a.m.

Chair: Nicola Burke, Manager, PAREXEL Consulting
Session: "Planning and Conducting Successful Investigators'
Meetings"
Time: 10:30 a.m. - 12:00 p.m.

Chair: Diego Glancszpigel, Director, PAREXEL International,
Latin
America
Session: "How to Assure Quality When Clinical Trials Are
Conducted in
Developing Countries"
Time: 10:30 a.m. - 12:00 p.m.

About the Conference
The Annual DIA Meeting is attended by pharmaceutical, biotechnology
and regulatory professionals from around the world. This year's
meeting will have over 350 sessions and more than 1,000 speakers.
Professionals who bring new medicines and vaccines to populations
around the world gather at the DIA meeting to learn about best
practices. For more information visit the DIA website at
http://www.diahome.org.

About PAREXEL

PAREXEL International Corporation is a leading global
bio/pharmaceutical services organization, providing a broad range of
knowledge-based contract research, medical marketing and consulting
services to the worldwide pharmaceutical, biotechnology and medical
device industries. Committed to providing solutions that expedite
time-to-market and peak-market penetration, PAREXEL has developed
significant expertise across the development and commercialization
continuum, from drug development and regulatory consulting to
clinical pharmacology, clinical trials management, medical education
and reimbursement. Perceptive Informatics, Inc., a subsidiary of
PAREXEL, provides advanced technology solutions, including medical
imaging, Clinical Trial Management Systems (CTMS), Interactive Voice
Response Systems (IVRS) and integration services. Headquartered near
Boston, Massachusetts, PAREXEL operates in 52 locations throughout
39 countries around the world, and has approximately 5,445
employees. For more information about PAREXEL International visit
http://www.PAREXEL.com.

This release contains "forward-looking" statements regarding future
results and events. For this purpose, any statements contained
herein that are not statements of historical fact may be deemed
forward-looking statements. Without limiting the foregoing, the
words "believes," "anticipates," "plans," "expects," "intends," "appe
ars," "estimates," "projects," "targets" and similar expressions are
also intended to identify forward-looking statements. The forward-
looking statements in this release involve a number of risks and
uncertainties. The Company's actual future results may differ
significantly from the results discussed in the forward- looking
statements contained in this release. Important factors that might
cause such a difference include, but are not limited to, risks
associated with: actual operating performance; actual expense
savings and other operating improvements resulting from recent
restructurings; the loss, modification, or delay of contracts which
would, among other things, adversely impact the Company's
recognition of revenue included in backlog; the amendment or
interpretation of Financial Accounting Standards Board Statement No.
123 (revised 2004), Share-Based Payment ("Statement 123R"), which
could change the Company's current assessment of the effects of the
adoption of Statement 123R on the acceleration of equity grants, the
assumptions inherent in equity pricing models under Statement 123R
and the final results of the closing of the Company's books for
future financial periods; the Company's dependence on certain
industries and clients; the Company's ability to win new business,
manage growth and costs, and attract and retain employees; the
Company's ability to complete additional acquisitions and to
integrate newly acquired businesses or enter into new lines of
business; the impact on the Company's business of government
regulation of the drug, medical device and biotechnology industry;
consolidation within the pharmaceutical industry and competition
within the biopharmaceutical services industry; the potential for
significant liability to clients and third parties; the potential
adverse impact of health care reform; and the effects of exchange
rate fluctuations and other international economic, political, and
other risks. Such factors and others are discussed more fully in the
section entitled "Risk Factors" of the Company's Quarterly Report on
Form 10-Q for the period ended March 31, 2006 as filed with the SEC
on May 9, 2006, which "Risk Factors" discussion is incorporated by
reference in this press release. The forward-looking statements
included in this press release represent the Company's estimates as
of the date of this release. The Company specifically disclaims any
obligation to update these forward-looking statements in the future.
These forward-looking statements should not be relied upon as
representing the Company's estimates or views as of any date
subsequent to the date of this press release.

PAREXEL is a registered trademark of PAREXEL International
Corporation, and Perceptive Informatics is a trademark of Perceptive
Informatics, Inc. All other names or marks may be registered
trademarks or trademarks of their respective business and are hereby
acknowledged.

Media Contact:
Jennifer Baird, Director of Public Relations
PAREXEL International
Tel: +1.781.434.4409
Email: Jennifer.Baird@PAREXEL.com

---------------------------------------------------------------------
-----------
Source: PAREXEL International Corporation

------------------------ Yahoo! Groups Sponsor --------------------~-->
Something is new at Yahoo! Groups. Check out the enhanced email design.
http://us.click.yahoo.com/SISQkA/gOaOAA/yQLSAA/H4xqlB/TM
--------------------------------------------------------------------~->

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Monday, June 12, 2006

Biotech News - TGen Foundation Announces Kristin Hornaday Fund

TGen Foundation Announces Kristin Hornaday Fund

Fund will help further TGen's Melanoma Research Programs

06-12-2006

Phoenix, Arizona, June 12, 2006--The TGen Foundation today announced
the creation of the Kristin Hornaday Fund for Melanoma Research.
Kristin, the daughter of RuthAnn and Tom Hornaday, lost her battle
with melanoma in June of 1993 at the age of 26.
Karen and Bill Clements, who are lifelong friends of the Hornadays,
started the fund, which has already raised over $65,000 to support
TGen's melanoma research programs.

Melanoma is the most dangerous and aggressive form of skin cancer.
The five-year survival rate for melanoma decreases dramatically
(from 96% to 12%) as the disease progresses from Stage I to Stage
IV. It kills more women aged 25-30 than any other cancer. Caught
early, melanoma has a cure rate of about 90%. However, there is no
proven standard therapy for high risk or advanced melanoma and no
new treatments have been introduced in thirty years.

Melanoma investigators at TGen are attacking familial and sporadic
melanoma on multiple fronts, furthering TGen's mission to develop
earlier diagnoses and smarter treatments. Research initiatives
include:

- Investigating how previously identified genes contribute to
melanoma progression.

- Studying large numbers of patient samples to improve the detection
of melanoma and identify previously unknown drug targets.

- Investigating a 100-gene region to identify a familial melanoma-
susceptibility gene.

"Generous people like the Hornadays and the Clements are helping
TGen to make an incredible impact on fighting terrible diseases such
as melanoma," said Michael Bassoff, president of the TGen
Foundation. "The Kristin Hornaday Fund for Melanoma Research will
enable our investigators to accelerate the research process and
bring breakthroughs to patients faster."

Kristin, nicknamed Kristi by her friends and family, brought joy to
all who knew her. She attended Xavier High School where she was
president of the student body. She graduated with honors from
Denison University in 1988 and was working in sales at IBM when she
was diagnosed with malignant melanoma in 1990. During the next three
years she went though periods where she was thought to be cancer
free, only to have the cancer return. Outstanding physicians at some
of the world's most renowned cancer centers treated her. She married
Greg Garrett in November of 1992, but even this storybook romance
could not save her from metastatic melanoma.

"Everyone in our family suffered greatly with Kristi's battle with
melanoma and we want to help other families avoid similar trauma,"
said Mr. Hornaday.

For more information or to contribute, visit the Kristin Hornaday
Fund for Melanoma Research.

# # #

About the TGen Foundation
The TGen Foundation is a non-profit organization. All donations made
to the TGen Foundation will be used to fund TGen's research needs
for improving the health of humankind as we target new treatments,
therapies and cures for such diseases as autism, melanoma,
pancreatic cancer, brain tumors and diabetes. Donors may designate
their gift as a tribute, either in memory or honor of a friend or
family member. There are many other ways to also support the TGen
Foundation. To discuss specific options with a Foundation staff
member, please call (602) 343-TGEN (8436) or visit
http://www.helptgen.org.

About TGen
The Translational Genomics Research Institute (TGen) is a non-profit
501(c)(3) organization focused on developing earlier diagnostics and
smarter treatments. Translational genomics research is a relatively
new field employing innovative advances arising from the Human
Genome Project and applying them to the development of diagnostics,
prognostics and therapies for cancer, neurological disorders,
diabetes and other complex diseases. TGen's research is based on
personalized medicine. The institute plans to accomplish its goals
through robust and disease-focused research.

http://groups.yahoo.com/group/biotech-news/
http://www.arizonabiotech.com/

------------------------ Yahoo! Groups Sponsor --------------------~-->
You can search right from your browser? It's easy and it's free. See how.
http://us.click.yahoo.com/_7bhrC/NGxNAA/yQLSAA/H4xqlB/TM
--------------------------------------------------------------------~->

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Tuesday, June 06, 2006

Biotech News - Rosetta Biosoftware Leverages Borland Application Lifecycle Management (ALM) Pro

Rosetta Biosoftware Leverages Borland Application Lifecycle
Management (ALM) Products to Help Customers Reduce the Time and Cost
of Drug Development

New System Developed with Borland Tools Used by the U.S. Food and
Drug Administration's Center for Drug Evaluation, Pharmaceutical
Companies, Premier Academic Institutions and Service Providers

http://www.arizonabiotech.com/

Borland Software Corporation (Nasdaq:BORL), the global leader for
Software Delivery Optimization (SDO), announced today that Rosetta
Biosoftware is using Borland's Application Lifecycle Management
(ALM) products to deliver well-defined, well-documented, high-
quality software for the pharmaceutical and biotech industries.
Rosetta Biosoftware leverages Borland's tightly integrated CaliberRM
(R), StarTeam(R) and Together(R) products along with the company's
Consulting and Education Services to manage its critical software
development processes. In recognition of its use of information
technology to benefit society, Rosetta Biosoftware was recently
named an IDG Computerworld Honors Program Laureate.

Rosetta Biosoftware is currently using Borland's ALM products to
streamline and automate the processes of requirements management,
software change and configuration management as well as visual
modeling and architectural design. The processes are critical to the
ongoing development of its flagship product, the Rosetta Resolver(R)
system.

http://groups.yahoo.com/group/biotech-news/

The Rosetta Resolver system offers life science researchers an
analysis and data management framework for gene expression which can
minimize costly and time-intensive downstream drug development. Life
science research organizations that have licensed the system include
many of the top pharmaceutical companies from around the world, as
well as premier academic institutions and service providers.

The U.S. Food and Drug Administration's (FDA) Center for Drug
Evaluation and Research (CDER) and National Center for Toxicological
Research (NCTR) are currently using the Rosetta Resolver system as
one of several platforms for the analysis of data submitted through
Voluntary Genomics Data Submissions (VGDS), through which microarray
data are submitted from companies engaged in drug development. Gene
expression data analysis is playing an increasing role in
pharmaceutical and biotech drug development in areas such as
toxicogenomics, clinical studies and molecular diagnostics. These
data open new opportunities to better understand diseases and
develop safer drugs more quickly.

Rosetta Biosoftware's primary goal is to empower researchers in drug
discovery and development to conduct cutting-edge research for
improving the quality of human life. Because its customers rely on
the Resolver system to enable the drug discovery process, they need
confidence in the software's accuracy and its ability to reproduce
analysis results. Customers also need confidence in Rosetta's
methods for developing and validating the software, which means
those development and validation methods must be transparent and
well-documented.

"Early on we realized we needed a comprehensive ALM solution like
the one Borland provides us to integrate, automate and document our
core development processes," explained Jim Pearson, manager of
quality assurance at Rosetta Biosoftware. "The life sciences
industry rapidly changes as information technology is applied to
more areas of research. It is imperative that we're able to quickly
deliver new features and functionality to address this rapidly
evolving market. To do that we needed a powerful but flexible system
that can support our rigorous requirements and easily adapt to our
methodologies."

Integrated ALM Products Help Increase Predictability of Software
Delivery

Rosetta Biosoftware leverages the tightly integrated and
customizable Borland CaliberRM technology to automate its specific
requirements processes and to track requirements from elicitation
through final delivery. Once the business, technical, functional and
operational requirements are entered into the Borland CaliberRM
system, stakeholders across the organization can easily map their
individual efforts back to the requirements and collaborate with
each other more effectively.

In addition, Borland StarTeam provides a robust platform for the
entire software delivery process. It promotes team communication and
collaboration through automated workflows and centralized control of
all project assets. Rosetta Biosoftware also enables its customers
to leverage this system to enter escalation and enhancement requests
for the Resolver product, and then extract web pages to view the
progress of their change requests.

The Rosetta Biosoftware team is also using Borland Together to help
bridge the communication gap between business and IT stakeholders.
Using this common set of visual modeling languages, Rosetta
Biosoftware is able to more accurately and efficiently define the
next release of the Resolver system. With support for business
process modeling, data modeling, application modeling and
visualization, and comprehensive audits and metrics for both models
and code, Borland Together helps the Rosetta's development team
accelerate delivery of a high-quality solution.

To learn more about Borland ALM solutions, please visit
www.borland.com/products.

About Borland

Founded in 1983, Borland Software Corporation (Nasdaq:BORL) is the
global leader in platform independent solutions for Software
Delivery Optimization. The company provides the software and
services that align the people, process, and technology required to
maximize the business value of software. To learn more about
delivering quality software, on time and within budget, visit
http://www.borland.com.

Borland, CaliberRM, StarTeam, Together and all other Borland brand
and product names are service marks, trademarks or registered
trademarks of Borland Software Corporation in the United States and
other countries. All other marks are the property of their
respective owners.

About the Computerworld Honors Program

Founded by International Data Group (IDG) in 1988, the Computerworld
Honors Program is governed by the not-for-profit Computerworld
Information Technology Awards Foundation. In its 18th year,
Computerworld Honors is the longest running global program to honor
individuals and organizations that use information technology to
benefit society. The 18th Annual Laureates Medal Ceremony & Gala
Awards Evening will take place on June 5, 2006 at the Andrew W.
Mellon Auditorium in Washington, D.C.

Safe Harbor Statement

This release contains "forward-looking statements" as defined under
the U.S. Federal Securities Laws, including the Private Securities
Litigation Reform Act of 1995 and is subject to the safe harbors
created by such laws. Forward-looking statements may relate to, but
are not limited to, the acceptance by existing or potential
customers of Borland's Software Delivery Optimization vision. Such
forward-looking statements are based on current expectations that
involve a number of uncertainties and risks that may cause actual
events or results to differ materially. Factors that could cause
actual events or results to differ materially include, among others,
the following: rapid technological change that can adversely affect
the demand for Borland products, shifts in customer demand, shifts
in strategic relationships, delays in Borland's ability to deliver
its products and services, software errors or announcements by
competitors. These and other risks may be detailed from time to time
in Borland periodic reports filed with the Securities and Exchange
Commission, including, but not limited to, its latest Annual Report
on Form 10-K and its latest Quarterly Report on Form 10-Q, copies of
which may be obtained from www.sec.gov. Borland is under no
obligation to (and expressly disclaims any such obligation to)
update or alter its forward-looking statements whether as a result
of new information, future events or otherwise. Information
contained in our website is not incorporated by reference in, or
made part of this press release

------------------------ Yahoo! Groups Sponsor --------------------~-->
Everything you need is one click away.  Make Yahoo! your home page now.
http://us.click.yahoo.com/AHchtC/4FxNAA/yQLSAA/H4xqlB/TM
--------------------------------------------------------------------~->

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News - Arizona Lays out Life Science Welcome Mat with Nearly $800 Million

Arizona Lays out Life Science Welcome Mat with Nearly $800 Million
in Planned Capital Investment, an Industrial Info News Alert
SUGAR LAND, Texas

June 6, 2006--Researched by Industrial Info Resources (Sugar Land,
Texas). Long a magnet for retirees seeking the sun, Arizona now
hopes to be equally successful in attracting the best and brightest
from the pharmaceutical-biotech industry. Currently, there are
sixteen projects that represent a total investment value (TIV) of
$796 million.

For details, including a listing of the sixteen projects, view the
entire article by subscribing to Industrialinfo.com's Premium
Industry News at http://www.industrialinfo.com/showNews.jsp?
newsitemID=89974, or browse other breaking industrial news stories
at www.industrialinfo.com.

Industrial Info Resources (IIR) is a Marketing Information Service
company that has been doing business for over 23 years. IIR is
respected as the leader in providing comprehensive market
intelligence pertaining to the industrial processing, heavy
manufacturing, and energy-related industries throughout the world.

------------------------ Yahoo! Groups Sponsor --------------------~-->
You can search right from your browser? It's easy and it's free. See how.
http://us.click.yahoo.com/_7bhrC/NGxNAA/yQLSAA/H4xqlB/TM
--------------------------------------------------------------------~->

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/